Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 6,533 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Subject Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

NCT05881993
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
CBP-4888, Placebo
Drug · Other
Lead sponsor
Comanche Biopharma
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

NCT04856293
View directory record Official record
Conditions
Healthy Participants
Interventions
Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability

NCT03329014
View directory record Official record
Conditions
Procedural Sedation
Interventions
Remimazolam, Placebo
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 21, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects

NCT02750384
View directory record Official record
Conditions
Healthy Volunteers, Bioavailability
Interventions
DSM265 50% SDD granules, DSM265 25% SDD powder for suspension
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 21, 2026, 10:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants

NCT07652723
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
Aspirin, BAY3389934
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

NCT06959888
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
ALG-055009
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers

NCT04598542
View directory record Official record
Conditions
Drug-Drug Interaction
Interventions
Lorecivivint (LOR), Triamcinolone acetonide (TA)
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

NCT01524770
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 22, 2014 · Synced Oct 21, 2026, 10:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

NCT07476118
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Brenipatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

NCT01674218
View directory record Official record
Conditions
Tuberculosis
Interventions
Moxifloxacin, PA-824, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

NCT00413790
View directory record Official record
Conditions
Healthy
Interventions
Darifenacin, Tolterodine, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
162 participants
Timeline
2006 – 2007
U.S. locations
12
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Icariin to Prevent Corticosteroid-related Memory Changes

NCT02112123
View directory record Official record
Conditions
the Pharmacokinetic Profile of Icariin in Humans
Interventions
Icariin, Matching placebo
Drug · Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers

NCT01935960
View directory record Official record
Conditions
Healthy Subject
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Retinoid 9cUAB30
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
3
States / cities
Birmingham, Alabama • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants

NCT06640920
View directory record Official record
Conditions
Healthy
Interventions
Cohort A, Cohort B, Cohort C, Cohort D
Biological
Lead sponsor
Uniquity One (UNI)
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT03565861
View directory record Official record
Conditions
Safety Issues
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 21, 2026, 10:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

4D-MRI for Precision Medicine

NCT04657042
View directory record Official record
Conditions
Healthy Volunteers, Liver Cancer, Lung Cancer
Interventions
Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 82 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects

NCT01860703
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Deferiprone, deferiprone matching placebo tablets, moxifloxacin, placebo
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

NCT01290042
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
AMG 181, Placebo for AMG 181
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
5
States / cities
Glendale, California • Bridgeport, Connecticut • Danbury, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078

NCT02567773
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects

NCT07364669
View directory record Official record
Conditions
Healthy Subjects
Interventions
Insulex® R (soluble human insulin, biosimilar), Humulin® R (soluble human insulin, biosimilar)
Drug
Lead sponsor
Laboratorios Pisa S.A. de C.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets

NCT05327491
View directory record Official record
Conditions
Healthy Participants
Interventions
Sotorasib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
4
States / cities
Daytona Beach, Florida • South Miami, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects

NCT03472313
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 21, 2026, 10:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

NCT02678988
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AI-1000 G2, PFS-NSD, Tocilizumab
Device · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 10:35 PM EDT